Chronic myelogenous leukemia, BCR-ABL1+

American Journal of Clinical Pathology

Volumn 132, Issue 2, 2009, Pages 250-260

  Vardiman, James W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

BCR ABL1; Chronic myelogenous leukemia; Philadelphia chromosome; Protein tyrosine kinase inhibitor; Tyrosine kinase domain mutation

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

BCR ABL1 GENE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONFERENCE PAPER; FUSION GENE; HUMAN; MOLECULAR GENETICS; NEUTROPHILIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; FUSION PROTEINS, BCR-ABL; GUIDELINES AS TOPIC; HUMANS; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE;

EID: 68549125412     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPUN89CXERVOVH     Document Type: Conference Paper

References (61)

1. Bennett JH. Two cases of disease and enlargement of the spleen in which death took place from the presence of purulent material in the blood. Edinburgh Med Surg. 1845;64:413-423.
2. Virchow R. Weisess blut. Froiep's Notizen. 1845;36:151-156.
3. Virchow R. Die Leukaemie. In: Gesammelte abhandlugen zur wissenschaftlichen medizin. Frankfurt, Germany: Meidinger; 1865:190-211.
4. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497-1500.
5. Rowley JD. Letter: a new consistent abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
6. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene adjacent to a translocation breakpoint in chronic myelogenous leukemia. Nature. 1983;306:277-280.
7. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.
8. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A. 1993;90:3755-3759.
9. Baccarini M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2006;108:1809-1820.
10. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
11. Savage DJ, Szydlo RM, Chase A, et al. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997;96:111-116.
12. Cotta CV, Bueso-Ramos CE. New insights into the pathobiology and treatment of chronic myelogenous leukemia. Ann Diagn Pathol. 2007;11:68-78.
13. Spiers AS, Bain BJ, Tumer JE. The peripheral blood in chronic granulocytic leukaemia: study of 50 untreated Philadelphiapositive cases. Scand J Haematol. 1977;18:25-38.
14. Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106:1306-1315.
15. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow features and clinical findings in chronic myeloid leukemia: a comparative, multicenter immunohistological and morphometric study on 614 patients. Leuk Lymphoma. 2000;36:295-308.
16. Buesche G, Hehlmann R, Hecker H, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia: prospective long-term results from a randomized-controlled trial. Leukemia. 2003;17:2444-2453.
17. Dekmezian R, Kantarjian HM, Keating JM, et al. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59:1739-1743.
18. Millot F, Traore P, Guilhot J, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116:140-143.
19. Rowe JM, Lichtman MA. Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood. 1984;63:1230-1234.
20. Maloisel F, Favre G, Mahmal L, et al. Isolated lytic lesions as extramedullary disease in chronic myelogenous leukemia: a report of three cases. Eur J Intern Med. 2005;16:288-290.
21. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375-2384.
22. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [published correction appears in Blood. 1997;89:4244]. Blood. 1996;88:2410-2414.
23. van Rhee F, Hochhaus A, Lin F, et al. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996;87:5213-5217.
24. Melo JV, Myint H, Galton DA, et al. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia: Leukemia. 1994;8:208-211.
25. V617F mutation [letter]. Blood. 2007;109:4106-4107.
26. V617F mutation emerged during treatment of chronic myelogenous leukemia [letter]. Leukemia. 2007;21:1103-1104.
27. Krämer A, Reiter A, Kruth J, et al. JAK2-V617F mutation in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Lancet Oncol. 2007;8:658-660.
28. Bornhauser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2 (V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis [letter]. Leukemia. 2007;21:1824-1826.
29. Bocchia M, Vannucchi AM, Gozzetti A, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8:864-866.
30. V617F mutation and BCR-ABL translocation in a patient with chronic myelogenous leukemia [letter] [published online ahead of print July 16, 2008]. Int J Hematol. 2008;88:243-245.
31. V617F-positive chronic idiopathic myelofibrosis. Leuk Res. 2008;32:1608-1610.
32. Krämer A. JAK2-V617F and BCR-ABL: double jeopardy [editorial]? Leuk Res. 2008;32:1489-1490.
33. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 1993;11(suppl 1):11-15.
34. Mitelman F, Levan G, Nilsson PG, et al. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976;18:24-30.
35. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441-453.
36. Gordon MY, Goldman JM. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br J Haematol. 1996;95:10-20.
37. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110:2-11.
38. Baccarani M, Russo D, Rosti G, et al. Interferon-alfa for chronic myeloid leukemia. Semin Hematol. 2003;40:22-33.
39. Apperley JF. Part 1: mechanism of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018-1029.
40. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
41. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following imatinib mesylate therapy. Blood. 2008;112:53-55.
42. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008;112:2112-2118.
43. Kantarjian HM, Talpaz M, Giles F, et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145:913-923.
44. Vardiman JW, Melo JV, Baccarani M, et al. Chronic myelogenous leukaemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:32-37.
45. WHO Classification of Tumours; vol 2.
46. Anastasi J, Feng J, Dickstein JI, et al. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast phase vs Ph+ acute lymphoblastic leukemia. Leukemia. 1996;10:795-802.
47. Schenk TM, Keyhani A, Bottcher S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 1998;12:666-674.
48. Secker-Walker LM, Craig JM. Prognostic implications of breakpoint and lineage heterogeneity in Philadelphia-positive acute lymphoblastic leukemia: a review. Leukemia. 1993;7:147-151.
49. Paietta E, Racevskis J, Bennett JM, et al. Biological heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group Experience. Leukemia. 1998;12:1881-1885.
50. Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia: retrospective study and review of literature. Leuk Res. 2004;28:579-586.
51. Soupir CP, Vergilio JA, Cin PD, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127:642-650.
52. Borowitz MJ, Bene MC, Harris NL, et al. Acute leukaemias of ambiguous lineage. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:150-155.
53. WHO Classification of Tumours; vol 2.
54. Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib. Leuk Lymphoma. 2004;45:695-698.
55. Fayad L, Kantarjian H, O'Brien S, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997;11:767-771.
56. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98:1905-1911.
57. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003;101:1941-1949.
58. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004;18:1340-1346.
59. Quintás-Cardama A, Kantarjian H, Abruzzo LV, et al. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy [letter]. Leukemia. 2007;21:2394-2396.
60. Navarro JT, Feliu E, Grau J, et al. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol. 2007;82:849-851.
61. Fialkow PJ, Martin PJ, Najfeld V, et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 1981;58:158-163.